血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂启动对COVID-19住院患者无器官支持天数的影响:一项随机临床试验
在7国69个中心进行的适应性平台随机试验中,721例危重和58例非危重COVID-19住院成人被随机分配接受ACE抑制剂、ARB、ARB联合DMX-200或无RAS抑制剂对照,用药至多10天。因安全顾虑于2022年2月25日停止入组。危重患者中,ACE抑制剂组和ARB组的无器官支持天数及医院生存率均低于对照组,后验概率显示很可能恶化结局。
要点
- 危重COVID-19患者启动ACE抑制剂或ARB未改善无器官支持天数,后验概率显示很可能恶化。
- ACE抑制剂组医院生存166/231(71.9%),ARB组152/217(70.0%),对照组182/231(78.8%)。
- 试验因安全顾虑于2022年2月25日停止入组。
核心结论
- 在危重COVID-19成人中,启动ACE抑制剂或ARB未改善临床结局,且很可能恶化临床结局。
研究设计与样本
- 正在进行的适应性平台随机临床试验,纳入721例危重和58例非危重COVID-19住院成人。
- 2021年3月16日至2022年2月25日在7国69个中心随机分组,最终随访2022年6月1日。
- 干预为开放标签启动ACE抑制剂(n=257)、ARB(n=248)、ARB联合DMX-200(n=10)或无RAS抑制剂对照(n=264),至多10天。
- 主要结局为21天内无器官支持天数,采用贝叶斯累积逻辑模型分析,OR大于1代表结局改善。
主要发现
- 危重患者中位无器官支持天数:ACE抑制剂组10(IQR -1至16,n=231),ARB组8(IQR -1至17,n=217),对照组12(IQR 0至17,n=231)。
- 与对照组相比,ACE抑制剂改善的中位调整OR为0.77(95%贝叶斯可信区间0.58-1.06),ARB为0.76(95%可信区间0.56-1.05)。
- ACE抑制剂和ARB使无器官支持天数恶化的后验概率分别为94.9%和95.4%。
- 医院生存:ACE抑制剂组166/231(71.9%),ARB组152/217(70.0%),对照组182/231(78.8%)。
- ACE抑制剂和ARB使医院生存恶化的后验概率分别为95.3%和98.1%。
临床怎么用
- 原文结论为危重COVID-19成人启动ACE抑制剂或ARB未改善且很可能恶化临床结局,未据此给出推荐。
局限性
- 因安全顾虑于2022年2月25日停止入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. OBJECTIVE: To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS: In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non-critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS: Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES: The primary outcome was organ support-free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS: On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support-free days among critically ill patients was 10 (-1 to 16) in the ACE inhibitor group (n = 231), 8 (-1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support-free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE: In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.
引用
- Lawler PR, Derde LPG, van de Veerdonk FL, et al. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA. 2023. PMID: 37039790. doi:10.1001/jama.2023.4480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。